Key Laboratory of Pathobiology, Department of Pathophysiology, Ministry of Education, College of Basical Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, China.
Int J Mol Sci. 2024 Jan 27;25(3):1577. doi: 10.3390/ijms25031577.
Systemic chronic inflammation (SCI) due to intrinsic immune over-activation is an important factor in the development of many noninfectious chronic diseases, such as neurodegenerative diseases and diabetes mellitus. Among these immune responses, macrophages are extensively involved in the regulation of inflammatory responses by virtue of their polarization plasticity; thus, dysregulation of macrophage polarization direction is one of the potential causes of the generation and maintenance of SCI. High-temperature demand protein A2 (HtrA2/Omi) is an important regulator of mitochondrial quality control, not only participating in the degradation of mis-accumulated proteins in the mitochondrial unfolded protein response (UPRmt) to maintain normal mitochondrial function through its enzymatic activity, but also participating in the regulation of mitochondrial dynamics-related protein interactions to maintain mitochondrial morphology. Recent studies have also reported the involvement of HtrA2/Omi as a novel inflammatory mediator in the regulation of the inflammatory response. HtrA2/Omi regulates the inflammatory response in BMDM by controlling TRAF2 stabilization in a collagen-induced arthritis mouse model; the lack of HtrA2 ameliorates pro-inflammatory cytokine expression in macrophages. In this review, we summarize the mechanisms by which HtrA2/Omi proteins are involved in macrophage polarization remodeling by influencing macrophage energy metabolism reprogramming through the regulation of inflammatory signaling pathways and mitochondrial quality control, elucidating the roles played by HtrA2/Omi proteins in inflammatory responses. In conclusion, interfering with HtrA2/Omi may become an important entry point for regulating macrophage polarization, providing new research space for developing HtrA2/Omi-based therapies for SCI.
系统性慢性炎症(SCI)由于固有免疫过度激活是许多非传染性慢性疾病发展的重要因素,如神经退行性疾病和糖尿病。在这些免疫反应中,巨噬细胞通过其极化可塑性广泛参与炎症反应的调节;因此,巨噬细胞极化方向的失调是 SCI 产生和维持的潜在原因之一。高温需求蛋白 A2(HtrA2/Omi)是线粒体质量控制的重要调节剂,不仅通过其酶活性参与未折叠蛋白反应(UPRmt)中错误积累的蛋白质的降解,以维持正常的线粒体功能,而且还参与调节线粒体动力学相关蛋白相互作用,以维持线粒体形态。最近的研究还报道了 HtrA2/Omi 作为一种新的炎症介质参与调节炎症反应。在胶原诱导性关节炎小鼠模型中,HtrA2/Omi 通过控制 TRAF2 的稳定来调节 BMDM 中的炎症反应;缺乏 HtrA2 可改善巨噬细胞中促炎细胞因子的表达。在这篇综述中,我们总结了 HtrA2/Omi 蛋白通过调节炎症信号通路和线粒体质量控制来影响巨噬细胞能量代谢重编程,从而参与巨噬细胞极化重塑的机制,阐明了 HtrA2/Omi 蛋白在炎症反应中的作用。总之,干扰 HtrA2/Omi 可能成为调节巨噬细胞极化的一个重要切入点,为基于 HtrA2/Omi 的 SCI 治疗提供了新的研究空间。